1. Home
  2. SKYE vs MGTX Comparison

SKYE vs MGTX Comparison

Compare SKYE & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • MGTX
  • Stock Information
  • Founded
  • SKYE 2012
  • MGTX 2015
  • Country
  • SKYE United States
  • MGTX United States
  • Employees
  • SKYE 11
  • MGTX N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • MGTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SKYE Health Care
  • MGTX Health Care
  • Exchange
  • SKYE Nasdaq
  • MGTX Nasdaq
  • Market Cap
  • SKYE 176.8M
  • MGTX 282.3M
  • IPO Year
  • SKYE N/A
  • MGTX N/A
  • Fundamental
  • Price
  • SKYE $6.19
  • MGTX $5.00
  • Analyst Decision
  • SKYE Strong Buy
  • MGTX Strong Buy
  • Analyst Count
  • SKYE 4
  • MGTX 2
  • Target Price
  • SKYE $19.25
  • MGTX $26.00
  • AVG Volume (30 Days)
  • SKYE 413.7K
  • MGTX 204.9K
  • Earning Date
  • SKYE 01-01-0001
  • MGTX 08-08-2024
  • Dividend Yield
  • SKYE N/A
  • MGTX N/A
  • EPS Growth
  • SKYE N/A
  • MGTX N/A
  • EPS
  • SKYE N/A
  • MGTX N/A
  • Revenue
  • SKYE N/A
  • MGTX $697,000.00
  • Revenue This Year
  • SKYE N/A
  • MGTX N/A
  • Revenue Next Year
  • SKYE N/A
  • MGTX $447.29
  • P/E Ratio
  • SKYE N/A
  • MGTX N/A
  • Revenue Growth
  • SKYE N/A
  • MGTX N/A
  • 52 Week Low
  • SKYE $1.44
  • MGTX $3.49
  • 52 Week High
  • SKYE $19.41
  • MGTX $7.60
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 38.95
  • MGTX 64.44
  • Support Level
  • SKYE $5.95
  • MGTX $4.55
  • Resistance Level
  • SKYE $6.83
  • MGTX $4.93
  • Average True Range (ATR)
  • SKYE 0.91
  • MGTX 0.21
  • MACD
  • SKYE 0.11
  • MGTX 0.12
  • Stochastic Oscillator
  • SKYE 44.20
  • MGTX 94.29

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About MGTX MeiraGTx Holdings plc

MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.

Share on Social Networks: